Correlation of the refined Hurley classification for hidradenitis suppurativa with patient‐reported quality of life and objective disease severity assessment

Hidradenitis suppurativa (HS) is a chronic, debilitating, heterogeneous disease requiring different treatment approaches. Recently, we refined the classic Hurley classification into a seven‐stage classification in order to guide these treatment choices. This new classification subdivides Hurley stage I and II into three substages, namely mild (A), moderate (B) and severe (C) HS disease. Hurley stage III is not subcategorized and is always severe.

[1]  D. Presser,et al.  Development and validation of the International Hidradenitis Suppurativa Severity Score System (IHS4), a novel dynamic scoring system to assess HS severity , 2017, The British journal of dermatology.

[2]  A. Vossen,et al.  Assessing Pruritus in Hidradenitis Suppurativa: A Cross-Sectional Study , 2017, American Journal of Clinical Dermatology.

[3]  A. Evers,et al.  Sexual health and quality of life are impaired in hidradenitis suppurativa: a multicentre cross‐sectional study , 2017, The British journal of dermatology.

[4]  E. Prens,et al.  Pathophysiology of hidradenitis suppurativa: An update. , 2015, Journal of the American Academy of Dermatology.

[5]  J. Lapins,et al.  European S1 guideline for the treatment of hidradenitis suppurativa/acne inversa , 2015, Journal of the European Academy of Dermatology and Venereology : JEADV.

[6]  A. Alavi,et al.  Quality-of-Life Impairment in Patients with Hidradenitis Suppurativa: A Canadian Study , 2015, American Journal of Clinical Dermatology.

[7]  G. Jemec,et al.  Depression in patients with hidradenitis suppurativa , 2013, Journal of the European Academy of Dermatology and Venereology : JEADV.

[8]  G. Jemec Clinical practice. Hidradenitis suppurativa. , 2012, The New England journal of medicine.

[9]  J. Szepietowski,et al.  Psychophysical aspects of hidradenitis suppurativa. , 2010, Acta dermato-venereologica.

[10]  C. Zouboulis,et al.  Comorbidities of hidradenitis suppurativa (acne inversa) , 2010, Dermato-endocrinology.

[11]  J. Lapins,et al.  Objective scoring of hidradenitis suppurativa reflecting the role of tobacco smoking and obesity , 2009, The British journal of dermatology.

[12]  H. Kurzen,et al.  What causes hidradenitis suppurativa? , 2008, Experimental dermatology.

[13]  G. Jemec,et al.  Morbidity in patients with hidradenitis suppurativa , 2001, The British journal of dermatology.

[14]  A. Finlay,et al.  Dermatology Life Quality Index (DLQI)—a simple practical measure for routine clinical use , 1994, Clinical and experimental dermatology.

[15]  E. Prens,et al.  Hurley Staging Refined: A Proposal by the Dutch Hidradenitis Suppurativa Expert Group. , 2017, Acta dermato-venereologica.

[16]  A. Kimball,et al.  The Handicap of Hidradenitis Suppurativa. , 2016, Dermatologic clinics.

[17]  A. Alikhan Hidradenitis Suppurativa. , 2016, JAMA dermatology.